Jennifer Brown, MD, PhD discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia.
Jennifer Brown, MD, PhD director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia (CLL).
The analysis of the trial focuses on patients with CLL, specifically without deletion 17p, due to the fact that more tolerable therapies and treatments which can induce lasting responses are needed for this high-risk patient population.
SEQUOIA, an international, phase 3, open-label, randomized study aims to evaluate zanubrutinib (Brukinsa) and how it compares to bendamustine and rituximab (Rituxan) for treatment in patients with CLL.
Transcription:
0:08 | This SEQUOIA study is a registration trial for zanubrutinib in CLL. And there's a primary analysis focused on patients without 17p deletion comparing single-agent zanubrutinib of single agent continuous therapy to bendamustine/rituximab. There was an RMC with single-agent zanubrutinib for patients with deletion 17p, and what was discussed during ASH talking for the first time is arm D, which is also focused on patients with 17 p deletion, but looking at the combination of zanubrutinib and venetoclax [Venclexta].
0:43 | The goal enrollment is 80 patients, and the study design involves 3 months lead-in with zanubrutinib followed by the addition of venetoclax for 12 to 25 months until disease progression, toxicity, or achievement of undetectable MRD with complete remission.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More